Oxford BioDynamics Plc, a biotechnology company, has announced that it expects to release its results for the year ended 30 September 2023 on Wednesday 17 January 2024. Following the release of the results, the company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors at 3pm GMT on the same day. The online presentation is open to both existing and potential shareholders, and questions can be submitted before or during the presentation.
The company's flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. The EpiSwitch® platform is used to develop and commercialize precision medicine tests for life-changing diseases. Additionally, the company has launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test), and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions, and it has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics, and an expertly curated 3D genome knowledge base comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
The company is headquartered in Oxford, UK, listed on AIM of the London Stock Exchange, and has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, as well as a reference laboratory in Penang, Malaysia. For more information, visit the company's website or follow OBD on Twitter and LinkedIn.
Oxford BioDynamics' EpiSwitch® platform, built on over 10 years of research, plays a crucial role in gene regulation by mapping the 3D configuration of the genome and identifying abnormal configurations to diagnose patients or determine how individuals might respond to a disease or treatment.